Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.410 enrolled

Overview

This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada.

Study Type

OBSERVATIONAL

Enrollment

410

Conditions

Glaucoma, Open-Angle Ocular Hypertension

Interventions

There is no intervention in this study.OTHER

This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects diagnosed at study visit or within 3 months of visit with OH * OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma) Exclusion Criteria: * No prior treatment for OH or OAG * No prior ocular surgery or history of ocular trauma

Locations (21)

Pfizer Investigational Site

Calgary, Alberta, Canada

Pfizer Investigational Site

Outcomes

Primary Outcomes

To describe the presence and distribution of risk factors in subjects diagnosed with OH or OAG stratified according to geographic distribution in a Canadian population in the ophthalmologist practice.

Time frame: duration of study

Secondary Outcomes

To describe the severity of disease at the time of diagnosis and to determine if there is a correlation between risk factors, or number of risk factors, and the severity of disease at presentation.

Time frame: duration of study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.